Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestonesNEW YORK and MELBOURNE, Australia, June 12, 2025 (GLOBE NEWSWIRE) -- ...

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL ...